SBFMW (Sunshine Biopharma) NonCurrent Deferred Liabilities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SBFMW Sunshine Biopharma Inc SBFMW
34 GF Score
Price $0.09
! 4 Warning Signs
View Full Analysis

What is Sunshine Biopharma NonCurrent Deferred Liabilities?

Sunshine Biopharma SBFMW 34 NonCurrent Deferred Liabilities is $0.00 Mil as of Jun. 2026. GuruFocus rates SBFMW with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Sunshine Biopharma's non-current deferred liabilities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Sunshine Biopharma NonCurrent Deferred Liabilities Related Terms

Sunshine Biopharma NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Sunshine Biopharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma NonCurrent Deferred Liabilities Chart

Sunshine Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.04 0.05 0.00 0.00

Sunshine Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SBFMW
34GF Score
Sunshine Biopharma Inc SBFMW
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Sunshine Biopharma (SBFMW) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Sunshine Biopharma and its competitors.
Is Sunshine Biopharma's NonCurrent Deferred Liabilities too high?
Sunshine Biopharma's current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Sunshine Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's NonCurrent Deferred Liabilities compare to BUDZ and CVSI?
Sunshine Biopharma's NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Sunshine Biopharma and its competitors. Sunshine Biopharma's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Sunshine Biopharma (SBFMW) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Sunshine Biopharma (SBFMW), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunshine Biopharma Business Description

Other Exchanges SBFM:USA
Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score

Get the complete analysis for SBFMW

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price